Table 2 Baseline characteristics of patients after 9–16 years of SVS (cohort 2)
ALL | HCC(-) | HCC(+) | ||
|---|---|---|---|---|
n = 1196 | n = 1156 | n = 40 | p-value | |
Sex(male,%) | 823 (68.8%) | 787 (68.1%) | 36 (90.0%) | 0.003 |
Age(years) | 53 (43, 63) | 52 (43, 62) | 64 (57, 72) | < 0.001 |
<40 | 501 (41.9%) | 496 (42.9%) | 5 (12.5%) | < 0.001 |
≥40 | 695 (58.1%) | 660 (57.1%) | 35 (87.5%) | |
Hypertension | 225 (18.8%) | 215 (18.6%) | 10 (25.0%) | 0.31 |
DM (%) | 135 (11.3%) | 122 (10.6%) | 13 (32.5%) | < 0.001 |
kidney disease | 92 (7.7%) | 88 (7.6%) | 4 (10.0%) | 0.58 |
Dyslipidaemia (%) | 125 (10.5%) | 123 (10.6%) | 2 (5.0%) | 0.25 |
BMI (kg/m2) | 22.32 (20.42, 24.45) | 22.32 (20.42, 24.42) | 23.025 (21.40, 25.39) | 0.091 |
<25 | 952 (79.6%) | 923 (79.8%) | 29 (72.5%) | 0.26 |
≥25 | 244 (20.4%) | 233 (20.2%) | 11 (27.5%) | |
AST (U/L) | 42 (25, 72.5) | 43 (25, 73.5) | 37.5 (27.5, 50.5) | 0.29 |
ALT (U/L) | 36 (25, 57) | 36 (25, 57) | 38 (30, 53) | 0.42 |
γGT (U/L) | 42 (22, 86) | 42 (22, 85) | 51.5 (32.5, 108.5) | 0.025 |
<56 | 731 (61.1%) | 709 (61.3%) | 22 (55.0%) | 0.42 |
≥56 | 465 (38.9%) | 447 (38.7%) | 18 (45.0%) | |
Total bilirubin (g/l) | 12 (9, 18) | 12 (9, 18) | 13.5 (9, 19) | 0.33 |
Albumin (g/dl) | 42.3 (37.5, 46) | 42.3 (37.5, 46.05) | 40.45 (35.05, 44) | 0.023 |
Platelet count (×10^9/L) | 156 (111, 197) | 156 (113, 197) | 110.5 (80, 156) | < 0.001 |
WBC (×10^9/L) | 5.16 (4.23, 6.395) | 5.16 (4.24, 6.41) | 5.00 (4.14, 5.32) | 0.086 |
FIB-4 score | 2 (2, 4) | 2 (2, 4) | 4 (2, 6) | < 0.001 |
≤ 3.25 | 824 (68.9%) | 810 (70.1%) | 14 (35.0%) | < 0.001 |
>3.25 | 372 (31.1%) | 346 (29.9%) | 26 (65.0%) | |
APRI score | 0 (0, 0) | 0 (0, 0) | 0 (0, 2) | 0.22 |
<2 | 901 (75.3%) | 874 (75.6%) | 27 (67.5%) | 0.24 |
≥2 | 295 (24.7%) | 282 (24.4%) | 13 (32.5%) | |
ALBI score | -2 (-4, -2) | -2 (-4, -2) | -2 (-4, -2) | 0.092 |
<-2.60 | 486 (40.6%) | 475 (41.1%) | 11 (27.5%) | 0.085 |
≥-2.60 | 710 (59.4%) | 681 (58.9%) | 29 (72.5%) | |
Creatinine (mg/dl) | 67 (57, 77) | 67 (57, 77) | 67 (56, 76.5) | 0.83 |
eGFR (mL/min/1.73 m2 ) | 94 (76, 112) | 94 (76, 113) | 93 (76, 110) | 0.43 |
≥60 | 1068 (89.3%) | 1034 (89.4%) | 34 (85.0%) | 0.37 |
<60 | 128 (10.7%) | 122 (10.6%) | 6 (15.0%) | |
AFP (ng/ml) | 4.14 (2.9, 8.09) | 4.14 (2.9, 7.68) | 5.8 (4.06, 13.6) | 0.057 |
<5.0 | 793 (66.3%) | 774 (67.0%) | 19 (47.5%) | 0.010 |
≥5.0 | 403 (33.7%) | 382 (33.0%) | 21 (52.5%) | |
PT(s) | 13.5 (13.1, 14.1) | 13.5 (13.1, 14) | 13.5 (13.5, 15.45) | 0.018 |
PTA(%) | 90 (82, 95) | 90 (82, 95.7) | 87.85 (71, 90) | 0.005 |
INR | 1.07 (1.04, 1.13) | 1.07 (1.04, 1.13) | 1.09 (1.07, 1.27) | 0.005 |
APTT(s) | 37.15 (35.35, 39.2) | 37.15 (35.3, 39.2) | 37.15 (36.2, 38.05) | 0.97 |
Glucose(mmol/l) | 5 (4.7, 5.6) | 5 (4.7, 5.6) | 5.1 (5, 6.2) | 0.065 |
HBeAg | 530 (44.3%) | 517 (44.7%) | 13 (32.5%) | 0.13 |
NA | 1196 | 1156 | 40 | |
Entecavir | 713 | 687(59.4%) | 26(65.0%) | 0.16 |
Lamivudine | 237 | 232(20.1%) | 5(12.5%) | |
Adefovir | 132 | 124(10.7%) | 8(20.0%) | |
Telbivudine | 105 | 104(9.0%) | 1(2.5%) | |
Tenofovir | 9 | 9(0.8%) | 0(0.0%) |